Novo Nordisk's stock has plummeted after the company released a disappointing forecast. The extent of the decline is reported to be as much as 17% and possibly even 72% in some context, with the stock now near its 5-year low. The outlook for the company, particularly regarding its obesity drugs, appears uncertain due to pricing pressure, leading to varying opinions on whether the stock is a buying opportunity or a value trap.